View Older Stories View More Recent Stories

Aug 25, 2022 06:46AM Merck (MRK) and AstraZeneca (AZN) Announces LYNPARZA Approved in Japan as Adjuvant Treatment for Patients With BRCA-Mutated, HER2-Negative High Recurrent Risk Breast Cancer
Aug 25, 2022 06:45AM LYNPARZA® (olaparib) Approved in Japan as Adjuvant Treatment for Patients With BRCA-Mutated, HER2-Negative High Recurrent Risk Breast Cancer
Aug 23, 2022 06:46AM Merck (MRK) Granted FDA Fast Track Designation for MK-2060
Aug 23, 2022 06:45AM Merck Receives Fast Track Designation from the U.S. FDA for MK-2060, an Investigational Anticoagulant Therapy
Aug 16, 2022 07:10AM AstraZeneca (AZN). Merck (MRK) Annound FDA Accepts Submission of sNDA for LYNPARZA in Combination With Abiraterone and Prednisone or Prednisolone for Patients with mCRPC
Aug 16, 2022 07:00AM FDA Accepts Submission of Supplemental New Drug Application for LYNPARZA® (olaparib) in Combination With Abiraterone and Prednisone or Prednisolone for Patients With Metastatic Castration-Resistant P
Aug 16, 2022 06:47AM Merck (MRK) Enters Deal with Orna Therapeutics to Develop RNA Technology
Aug 16, 2022 06:45AM Merck and Orna Therapeutics Collaborate to Advance Orna’s Next Generation of RNA Technology
Aug 9, 2022 08:00AM MilliporeSigma Becomes One of the First CDMOs to Provide Full Viral Vector Offering with Launch of VirusExpress® 293 Adeno-Associated Virus Production Platform
Aug 4, 2022 06:45AM LYNPARZA® (olaparib) Approved in the EU as Adjuvant Treatment for Patients With Germline BRCA-Mutated, HER2-Negative High-Risk Early Breast Cancer
Aug 3, 2022 06:45AM Merck and Eisai Provide Update on Phase 3 LEAP-002 Trial Evaluating KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) Versus LENVIMA Monotherapy in Patients With Unresectable Hepatocellular Carci
Aug 3, 2022 06:42AM Merck (MRK) Announces Phase 3 KEYNOTE-921 Trial Did Not Meet Endpoints
Aug 3, 2022 06:40AM Merck Provides Update on Phase 3 KEYNOTE-921 Trial Evaluating KEYTRUDA® (pembrolizumab) Plus Chemotherapy in Patients With Metastatic Castration-Resistant Prostate Cancer
Jul 28, 2022 06:30AM Merck Announces Second-Quarter 2022 Financial Results
Jul 26, 2022 12:40PM Merck Announces Fourth-Quarter 2022 Dividend
Jul 20, 2022 06:47AM Merck (MRK) Reports Phase 3 KEYNOTE-412 Trial Did Not Meet Primary Endpoint
Jul 20, 2022 06:45AM Merck Provides Update on Phase 3 KEYNOTE-412 Trial in Unresected Locally Advanced Head and Neck Squamous Cell Carcinoma
Jul 18, 2022 12:00PM MilliporeSigma Breaks Ground on Company's First Lateral Flow Membrane Production Facility in the United States
Jul 13, 2022 09:00AM Micron to Select Athinia™ for Pioneering Data Collaboration
Jul 13, 2022 06:06AM Merck (MRK) Collaborates with Orion for Development and Commercialization of ODM-208
Jul 13, 2022 06:00AM Merck and Orion Announce Global Collaboration for the Development and Commercialization of ODM-208, an Investigational Steroid Synthesis Inhibitor for the Treatment of Metastatic Castration-Resistant
Jun 29, 2022 07:00AM Merck Announces the Launch of the Merck Digital Sciences Studio to Help Healthcare Startups Quickly Bring their Innovations to Market
Jun 29, 2022 06:45AM Merck to Hold Second-Quarter 2022 Sales and Earnings Conference Call July 28
Jun 27, 2022 06:45AM LYNPARZA® (olaparib) Receives Positive Opinion From EU CHMP as Adjuvant Treatment for Germline BRCA-Mutated, HER2-Negative High-Risk Early Breast Cancer
Jun 24, 2022 06:45AM Merck (MRK) Announces EU Approval of KEYTRUDA as Adjuvant Treatment for Adult and Adolescent Patients With Stage IIB or IIC Melanoma Following Complete Resection
Jun 24, 2022 06:45AM European Commission Approves KEYTRUDA® (pembrolizumab) as Adjuvant Treatment for Adult and Adolescent Patients (≥12 Years of Age) With Stage IIB or IIC Melanoma Following Complete Resection
Jun 23, 2022 09:00AM MilliporeSigma Opens US$ 65 Million CDMO Facility to Address Demand for Critical Cancer Therapies
Jun 23, 2022 05:57AM Merck (MRK) Announces CDC’s ACIP Unanimously Votes to Provisionally Recommend Use of VAXNEUVANCE as an Option for Pneumococcal Vaccination in Infants and Children
Jun 22, 2022 06:28PM CDC’s ACIP Unanimously Votes to Provisionally Recommend Use of Merck’s VAXNEUVANCE™ (Pneumococcal 15-valent Conjugate Vaccine) as an Option for Pneumococcal Vaccination in Infants and Children
Jun 22, 2022 06:46AM Merck (MRK) Announces FDA Approval of VAXNEUVANCE for Prevention of Invasive Pneumococcal Disease in Infants and Children
Jun 22, 2022 06:45AM U.S. FDA Approves Merck’s VAXNEUVANCE™ (Pneumococcal 15-valent Conjugate Vaccine) for the Prevention of Invasive Pneumococcal Disease in Infants and Children
Jun 21, 2022 04:30PM Results From Phase 3 PROpel Trial of LYNPARZA® (olaparib) Plus Abiraterone in First-Line Metastatic Castration-Resistant Prostate Cancer Published in NEJM Evidence
Jun 21, 2022 04:10PM Merck (MRK) Appoints Chirfi Guindo to Lead Marketing for Merck Human Health
Jun 21, 2022 04:10PM Merck Announces that Chirfi Guindo will Lead Marketing for Merck Human Health
Jun 21, 2022 07:14AM Merck (MRK) Presents Positive Results from Phase 1/2 Study Evaluating V116, the Company’s Investigational Pneumococcal Conjugate Vaccine for Adults
Jun 21, 2022 06:45AM Merck Presents Positive Results from Phase 1/2 Study Evaluating V116, the Company’s Investigational Pneumococcal Conjugate Vaccine for Adults
Jun 13, 2022 06:47AM Merck (MRK) Announces FDA Accepted Application for KEYTRUDA as Adjuvant Therapy for Stage IB (≥4 centimeters)-IIIA Non-Small Cell Lung Cancer Following Complete Surgical Resection
Jun 13, 2022 06:45AM FDA Accepts Application for Merck’s KEYTRUDA® (pembrolizumab) as Adjuvant Therapy for Stage IB (≥4 centimeters)-IIIA Non-Small Cell Lung Cancer Following Complete Surgical Resection
Jun 8, 2022 06:51AM Merck to Participate in the 2022 Goldman Sachs 43rd Annual Global Healthcare Conference
Jun 7, 2022 06:46AM Merck (MRK) and Ridgeback Announce New Data For Investigational LAGEVRIO™ (molnupiravir) From Phase 3 MOVe-OUT Study
Jun 7, 2022 06:45AM Merck and Ridgeback Announce New Data For Investigational LAGEVRIO™ (molnupiravir) From Phase 3 MOVe-OUT Study
Jun 7, 2022 06:34AM Merck (MRK) to Hold Investor Event to Highlight Oncology Portfolio and Pipeline
Jun 7, 2022 06:30AM Merck to Hold Investor Event to Highlight Oncology Portfolio and Pipeline
Jun 6, 2022 05:53AM Merck (MRK) Announces Adjuvant Treatment with KEYTRUDA Demonstrates Statistically Significant & Clinically Meaningful Improvement in Distant Metastasis-Free Survival in Patients With Resected Stage II
Jun 5, 2022 08:00AM Adjuvant Treatment With Merck’s KEYTRUDA® (pembrolizumab) Demonstrates Statistically Significant & Clinically Meaningful Improvement in Distant Metastasis-Free Survival in Patients With Resecte
May 24, 2022 01:46PM Merck Announces Third-Quarter 2022 Dividend
May 24, 2022 06:46AM Merck (MRK) Announces EU Approval of KEYTRUDA Plus Chemotherapy as Neoadjuvant Treatment, Then Continued as Adjuvant Monotherapy After Surgery for Locally Advanced or Early-Stage Triple-Negative Breas
May 24, 2022 06:45AM European Commission Approves KEYTRUDA® (pembrolizumab) Plus Chemotherapy as Neoadjuvant Treatment, Then Continued as Adjuvant Monotherapy After Surgery for Locally Advanced or Early-Stage Triple-Nega
May 20, 2022 08:15AM Merck (MRK) Receives Positive EU CHMP Opinion for KEYTRUDA as Adjuvant Treatment for Adult and Adolescent Patients With Stage IIB or IIC Melanoma
May 20, 2022 08:15AM Merck Receives Positive EU CHMP Opinion for KEYTRUDA® (pembrolizumab) as Adjuvant Treatment for Adult and Adolescent (≥12 Years of Age) Patients With Stage IIB or IIC Melanoma Following Complete Re
View More Recent Stories View Older Stories